Genetic aberrations in Wilms tumors discussed as potential targets for molecular interventions include WT1, CTNNB1, WTX, TP53, FBXW7, MYCN, SIX 1/2, DICER1, DROSHA, DGCR8, and IGF2, but preclinical data has become available only recently [431]. This evidence concerns the gene WT1 and Nephroblastoma.